A New Neurotech Startup Launches to Rival Sam Altman’s Merge Labs
AI-summarised brief · reviewed before publication
Bridge Neurotech announced its launch with $13.5 million in venture funding, including backing from General Catalyst. The San Francisco‑based startup aims to commercialize a wearable brain‑computer interface (BCI) that uses ultrasound to detect blood‑flow changes linked to neural activity, positioning itself as a non‑surgical alternative to implant‑based systems such as Elon Musk’s Neuralink. Founder and CEO Will Biederman, who contributed to Neuralink’s early chip design during his PhD, says the goal is broader accessibility, noting that only about 100 people have received implanted BCIs in clinical trials. Bridge’s technology builds on work from Arbor Neuroscience (formerly Forest Neurotech), which also spun out Sam Altman’s Merge Labs, both of which are testing ultrasound‑based brain imaging instruments in the UK. The company hopes to overcome the signal‑quality limitations of external sensors while avoiding the risks of neurosurgery.
💡 Why It Matters
- · By targeting a wearable, ultrasound‑based BCI, Bridge could open neural‑interface applications to consumers who are unwilling or unable to undergo brain surgery, expanding the market beyond the niche of clinical trial participants.